ClinicalTrials.gg
Active, not recruitingNCT04769037SINT1AUpdated Dec 13, 2024

Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity

An interventional study of B. infantis and Placebo in Diabetes Mellitus, Type 1, sponsored by Helmholtz Zentrum München. Active, not recruiting at 8 sites in 5 countries. Open to participants aged 7 Days to 6 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by Helmholtz Zentrum München · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,149
Allocation
Randomized
Ages
7 Days to 6 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 294 studies in Diabetes Mellitus, Type 1 with a site in Germany — 22 open to participants now, 30 under way, 6 of them phase 3. Diabetes Mellitus, Type 1 · Germany.

Enrollment
7th of 260
1,149 · median 61
Started
2021
with 10 others
No phase
43 of 294
4 open now
Primary completion
2027-10
later than 15 of 29 live
Registered
246th of 294
by date

Among the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany, this one is the 7th largest by enrollment of the 260 interventional ones that give a count, is one of 11 that started in 2021, is one of 43 with no phase, reaches primary completion later than 15 of the 29 other live ones, and was the 246th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

22 of the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 7 Days to 6 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 294 studies in Diabetes Mellitus, Type 1 with a site in Germany, or all of them as a file.
02

Study summary

Investigator initiated, randomised, placebo-controlled, double-blind, multi-centre primary intervention study to assess whether daily administration of B. infantis EVC001 from age 7 days to 6 weeks (+14 days) until age 12 months (+ 14 days) to children with elevated genetic risk for type 1 diabetes reduces the cumulative incidence of beta-cell autoantibodies in childhood.

Read the detailed description

The GPPAD-04 SINT1A study will evaluate whether early, regular supplementation with a daily dose of a probiotic can reduce the risk of developing beta-cell autoimmunity in children identified by GPPAD-02 as being genetically predisposed to developing type 1 diabetes. Children will be enrolled at age 7 days to 6 weeks (+14 days) and the study product (B. infantis EVC001 or Placebo) will be administered orally once per day from enrollment until age 12 months (+14 days).

The hypotheses is that administration of B. infantis may have a positive influence on the intestinal flora and thus have a regulating effect on the immune system. The study is designed to investigate whether pathogenic immune reactions as in type 1 diabetes but also in other diseases, such as celiac disease, can be reduced and if the disease can be prevented.

Children will be followed until age 3.5 - 6.5 years (2.5 - 5.5 years after end of treatment).

Throughout the study data will be collected by regular study visits, phone calls with the families and electronic questionaires.

Blood samples will be collected to investigate glucose, HbA1c, beta-cell autoantibodies, transglutaminase antibodies, vaccine responses, genetic susceptibility and mechanistic markers. Stool samples will be collected for further assessments such as colonization,microbiome, pH and calprotectin.

Exploratory outcomes (allergy, vaccine responses, stool microbiome, blood metabolomics, stool pH and calprotectin or site specific ancillary measurements) may be assessed or in part assessed on a portion of the participants after unblinding the study. They may not necessarily be included in the primary outcome analysis and publication.

GPPAD is committed to sharing of data in compliance with all applicable European and GPPAD Consortium Member State, Data Protection and Privacy Protection laws, rules and regulations.

Pseudonymized data of the GPPAD-04 SINT1A study will be available to the scientific community after the publication of the trial analysis, which is anticipated in 2028. The SINT1A data will be available upon request.

03

Conditions studied

  • Diabetes Mellitus, Type 1

Keywords

  • Type 1 diabetes autoimmunity
  • celiac autoimmunity
  • respiratory infections
  • allergy
  • prevention
  • probiotic
  • B. infantis
04

Who can participate

Ages eligible
7 Days to 6 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Infants between the ages of 7 days and 6 weeks (+14 days in case of illness or COVID-19 related issues or unexpected delay in result reporting) at the time of randomisation.
  2. A 10% or higher genetic risk to develop multiple beta-cell autoantibodies by age 6 years:

    1. For infants without a first-degree family history of type 1 diabetes, high genetic risk is defined as a DR3/DR4-DQ8 or DR4-DQ8/DR4-DQ8 genotype and a genetic risk score that is in the upper 25th centile (>14.4) or a DR3/DR4-DQ8 genotype with a GRS between the upper 50th (14.0) and 25th centile and a GG genotype at the rs3763305 SNP. These represent around 1% of all newborns.
    2. For infants with a first-degree family history of type 1 diabetes, high genetic risk is defined as having HLA DR4 and DQ8, and none of the following protective alleles: DRB1*1501, DQB1*0503, DRB1*1303. These represent around 30% of infants with a first-degree family history of T1D.
  3. Written signed by the custodial parent(s).-

Exclusion criteria

Exclusion Criteria:

  1. Any medical condition, concomitant disease or treatment that may interfere with the assessments or may jeopardize the participant's safe participation in the study, as judged by the Investigators.
  2. Preterm delivery \< 36 weeks of gestation.
  3. Proven immunodeficiency.
  4. Any condition that could be associated with poor compliance.5. Diagnosis of diabetes at the time of recruitment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,149 participants (actual)

Study arms

  • Active comparator
    B. infantis

    Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day

    Dietary Supplement: B. infantis

  • Placebo comparator
    Placebo

    Lactose identical in appearance and taste to the active supplement

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementB. infantis

    Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day

  • Dietary supplementPlacebo

    Lactose identical in appearance and taste to the active supplement

06

What researchers measure

Primary outcomes

  1. Persistent confirmed multiple beta-cell autoantibodies

    Persistent confirmed multiple beta-cell autoantibodies is defined as confirmed IAA, confirmed GADA, confirmed IA-2A, or confirmed ZnT8A in two consecutive samples, AND a confirmed second antibody from these four antibodies in one sample. The primary outcome is the elapsed time from the random treatment assignment to the first confirmed autoantibody positive sample used in defining the persistent confirmed multiple beta-cell autoantibody positive status. Diabetes in the absence of multiple beta-cell autoantibodies is also considered as a primary outcome endpoint, and in this case, the date of diagnosis is the time of the end point.

    Time frame: Through study completion, up to 6.5 years

Secondary outcomes

  1. Persistent confirmed beta-cell autoantibodies

    Any persistent confirmed beta-cell autoantibody, defined as at least one confirmed autoantibody in two consecutive samples, including IAA, GADA, IA-2A or ZnT8A

    Time frame: Through study completion, up to 6.5 years

  2. Diabetes

    Criteria for T1D onset are, as defined by the American Diabetes Association (ADA), based on glucose testing, or the presence of unequivocal hyperglycaemia with acute metabolic decompensation (diabetic ketoacidosis).

    Time frame: Through study completion, up to 6.5 years

  3. Transglutaminase antibodies

    Transglutaminase antibodies defined as persistent in two consecutive samples

    Time frame: Through study completion, up to 6.5 years

  4. Respiratory infection rate

    Respiratory infection rate in first year of life during supplementation

    Time frame: 1 year

  5. Measurement of Safety parameters

    Adverse Events and Serious Adverse Events will be captured until 30 days after the last administration of the food product. Local and systemic adverse effects will be elicited by direct questioning of the participant or parent. Systemic effects will be sought by questioning about any untoward symptoms or signs, and graded as mild, moderate, severe, life-threatening or death according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.

    Time frame: from Baseline until 30 days after end of supplementation

Other outcomes

  1. Allergy

    Participant's parents will be asked to complete questionnaires to obtain information about allergies every 12 months. Analyses will compare the B. infantis supplementation and placebo groups for the frequency of allergy and allergy sub-groups as defined form the yearly questionnaires.

    Time frame: Through study completion, up to 6.5 years

  2. Antibody response (IgG titres) to vaccines

    Information about rotavirus and MMR vaccination will be collected from parents and antibody response (IgG titers) will be measured centrally.

    Time frame: at age 6 months (rotavirus) and at age 2 years (MMR)

  3. Alterations of the gut microbiome or blood metabolome

    Exploratory analyses will examine the associations between B. infantis supplementation and mouth and stool organisms (microbiome), and blood markers such as the metabolome.

    Time frame: from baseline to age 12 months

  4. Stool pH

    Stool pH levels will be compared between B. infantis supplementation and placebo groups in a subset of children

    Time frame: at age 6 months

  5. Stool calprotectin

    Stool calprotectin levels will be compared between B. infantis supplementation and placebo groups in a subset of children

    Time frame: at age 6 months

07

Study locations

8 sites
  • University Hospitals Leuven Faculty of Medicine, Catholic University of Leuven
    Leuven, Belgium
  • Universitätsklinikum Carl Gustav Carus Technische Universität Dresden
    Dresden, Germany
  • AUF DER BULT, Kinder- und Jugendkrankenhaus
    Hannover, Germany
  • Institute of Diabetes Research, Helmholtz Zentrum Munich, Germany, and Forschergruppe Diabetes, Technical University Munich (TUM), School of Medicine, Klinikum rechts der Isar
    Munich, Germany
  • Department of Paediatrics Medical University of Warsaw
    Warsaw, Poland
  • Lund University, Skane University Hospital SUS
    Malmö, Sweden
  • University Department of Paediatrics, Cambridge Biomedical Campus
    Cambridge, United Kingdom
  • Royal Victoria Infirmary, Newcastle upon Tyne
    Newcastle, United Kingdom
08

References and documents

Publications

  • Ziegler AG, Arnolds S, Kolln A, Achenbach P, Berner R, Bonifacio E, Casteels K, Elding Larsson H, Gundert M, Hasford J, Kordonouri O, Lundgren M, Oltarzewski M, Pekalski ML, Pfirrmann M, Snape MD, Szypowska A, Todd JA; GPPAD STUDY GROUP. Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol. BMJ Open. 2021 Nov 9;11(11):e052449. doi: 10.1136/bmjopen-2021-052449. PubMed 34753762 ↗

Related links

Individual participant data

Plan to share: No — GPPAD is committed to sharing of data in compliance with all applicable European and GPPAD Consortium Member State, Data Protection and Privacy Protection laws, rules and regulations. Pseudonymized data of the GPPAD-04 SINT1A study will be available to the scientific community after the publication of the trial analysis, which is anticipated in 2028. The SINT1A data will be available upon request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Oct 2027, 78 months after the start.

Of 105 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 78 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2021
First posted
Feb 24, 2021
StartActual
Apr 22, 2021
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04769037
Lead sponsor
Helmholtz Zentrum München
Collaborators
Technical University of Munich, Kinderkrankenhaus auf der Bult, University Hospital Carl Gustav Carus, Skane University Hospital, Universitaire Ziekenhuizen KU Leuven, Medical University of Warsaw, Cambridge Biomedical Campus, Cambridge, UK, Royal Victoria Infirmary, Newcastle upon Tyne, UK
Responsible party
Anette-Gabriele Ziegler (Director - Institute of Diabetes Research, Helmholtz Zentrum München) — Principal investigator
First posted
Feb 24, 2021
Start date
Apr 22, 2021
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Dec 13, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion